Investor Relations
Alseres Pharmaceuticals, Inc (NASDAQ: ALSE) is a biotechnology company engaged in the development of biopharmaceutical products for the treatment of traumatic injuries and degenerative diseases. The Company maintains a world-class position in the field of regenerative therapeutics. Our energy and focus are reflected in several important initiatives. Our lead candidate, Cethrin®, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, has reported positive interim results in a Phase I/IIa clinical trial. Our molecular imaging program has a product candidate, ALTROPANE® molecular imaging agent, in Phase 3 clinical development. ALTROPANE® is a diagnostic tool intended to aid in differentiating Parkinsonian tremors from non-Parkinsonian or Essential Tremor. The Company's research and pre-clinical CNS programs include Inosine for the treatment of spinal cord injury and stroke, a DAT blocker for the treatment of Parkinson's disease, and a second generation technetium-based molecular imaging agent for PD and ADHD. Our sponsored scientific research in ground-breaking regenerative technologies may someday make possible other therapies for stroke, spinal cord and ocular injuries, bone repair and cardiovascular indications.
Stock Quote 07/24/08
- 4:00 PM ET
| ALSE | NASD |
| Price: | $2.20 |
| Change: | |
| Quotes delayed at least 20 minutes. Information provided by TurboFeed. |
|
Featured Reports
| 2007 10-K |
|
964.5 KB |
| 2007 Proxy Statement |
|
183.1 KB |
Recent News
Jun 30, 2008
Alseres Pharmaceuticals, Inc. Raises $5 Million










